European Society of Endocrinology

https://www.ese-hormones.org/advocacy/

None declared

Promotes their own interests or the collective interests of their members

Jan 2020 - Dec 2020

100,000€ - 199,999€

None declared

100,000€ - 199,999€

None declared

none

N/A

On 4 May 2021, the European Society of Endocrinology introduced its White Paper ‘Hormones in European Health Policies: How endocrinologists can contribute towards a healthier Europe’. This 40 page document introduces the policy makers to areas where increased attention to endocrine aspects of health and disease can benefit health policy making and can be found at https://www.ese-hormones.org/publications/policy-white-paper/.

The White Paper was the subject of a webinar organized on 4 May 2021, with the participation of members of the European Commission (John F Ryan, Christina de Avila, Jose Valverde) as well as members of the European Parliament (Cristian Silviu Busoi, Sirpa Pietikainen, Christel Schaldemose). At the occasion of the annual European Congress of Endocrinology, a digital event held in May 2021, EU Commissioner Stella Kyriakides addressed the audience of close to 4000 health care professionals addressing the endocrine health perspectives in the European health policies.

With regard to the European Beating Cancer Plan, ESE provided comments to the provisions in the draft plan in early 2021, and provided also additional perspectives towards members of the European Parliament ahead of the introduction of the plan of commissioner Stella Kyriakides on 4 February 2021. Specific aspects related to the prevention of certain cancers by focussing on the rising rates of obesity and the exposure to endocrine disruptors as risk factors to develop these specific cancers were highlighted. This also resulted in the inclusion of such specific concerns in the final report from the BECA committee, published by MEP Véronique Trillet-Lenoir in early 2022.

ESE joined several consultation processes, including those related to the European Health Data Space, and interacted through its membership of the Biomedical Alliance for Research in Europe with the incoming In Vitro Devices Regulation, addressing key issues around the transition from the existing framework towards the future one. These issues primarily related to the short timelines by which elements of the IVDR would be implemented, putting diagnostic laboratory routines specifically in the area of rare diseases at risk. This resulted in the necessary changes towards the timeline by which certain aspects of the new IVDR regulation would be implemented.

In the area of the Green Deal and the Chemicals Strategy for Sustainability the ESE Expert group on Endocrine Disruption provided input to several consultations, and organized together with our paediatric sister society – the European Society of Paediatric Endocrinology (ESPE) – a symposium as part of the 3rd Annual Forum on Endocrine Disruptors, organised by the European Commission (September 21-22 2021). This symposium was dedicated to the impact of endocrine disruption across the lifetime.

ESE is committed to provide the European Institutions with the expert knowledge and advice addressing the different areas of health policy making where the endocrine (hormonal) perspective needs to be considered. This has also been evidenced by the COVID-19 crisis, where patients with endocrine and metabolic diseases, particularly obesity and diabetes, have been particularly vulnerable, at risk of being hospitalized, and been subject of increased mortality.

The European Society of Endocrinology has over 4 000 direct individual members. In addition, through the ESE Council of Affiliated Societies, we work closely with our Affiliated National Endocrine Societies across Europe, representing over 25 500 European endocrinologists.

We also collaborate with other specialist societies working on sub-topics within endocrinology.

This enables us to develop positions and responses which are truly representative of the endocrine community within Europe. We respect this responsibility and aim to ensure that we provide practical and beneficial input into issues of relevance within the EU.

1 meetings found. Download meetings

The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

• Date	18 Feb 2020	Location	Brussels
  Subject	EU strategy on endocrine disruptors
  DG	Environment
  Attending	Daniel Calleja Crespo (Director-General)